PRIMARY STUDY
Synaptic changes induced by cannabinoid drugs and cannabis use disorder
Key Findings: This expansive review covers the current research on the neurobiological effects of short and long-term phytocannabinoid use as well as synthetic cannabinoid exposure based on animal models and humans. It highlights the need for better research on the associated risk of these compounds as it relates to cannabis use disorder (CUD).
Type of Study: Meta-analysis
Study Result: Inconclusive
Research Location(s): United States
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinol (CBN), CP-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 18, GPCR 55, GPCR, TRPs, PPARs
Ligands Studied: Dopamine, GABA, Glutamate, Serotonin
Citation: Augustin SM and Lovinger DM. Synaptic changes induced by cannabinoid drugs and cannabis use disorder. Neurobiol Dis. 2022; 167:105670. doi: 10.1016/j.nbd.2022.105670
Authors: Augustin SM, Lovinger DM
